Evidence map›Paper›PMID 25838138›Full record

ArticleNeuro-oncology2015

Oncolytic measles virus efficacy in murine xenograft models of atypical teratoid rhabdoid tumors.

Adam W Studebaker, Brian Hutzen, Christopher R Pierson, Terri A Shaffer, Corey Raffel, Eric M Jackson

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuro-oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 30 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Oncolytic viral vectors in the era of diversified cancer therapy: from preclinical to clinical.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022
    Review
  10. Review
  11. Review
  12. Delta-24-RGD, an Oncolytic Adenovirus, Increases Survival and Promotes Proinflammatory Immune Landscape Remodeling in Models of AT/RT and CNS-PNET.Clinical cancer research : an official journal of the American Association for Cancer Research · 2021
    Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Nonviral polymeric nanoparticles for gene therapy in pediatric CNS malignancies.Nanomedicine : nanotechnology, biology, and medicine · 2020
    Article
  18. Syncytia Formation in Oncolytic Virotherapy.Molecular therapy oncolytics · 2019
    Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Adam W StudebakerCenter for Childhood Cancer and Blood Diseases, Research Institute at Nationwide Children's Hospital, Columbus, Ohio (A.W.S., B.H.); Nationwide Children's Hospital Department of Pathology and Laboratory Medicine and Departments of Pathology and Anatomy, The Ohio State University College of Medicine, Columbus, Ohio (C.R.P.); Animal Resources Core, Research Institute at Nationwide Children's Hospital, Columbus, Ohio (T.A.S.); Department of Neurological Surgery and Pediatrics, University of California, San Francisco, California (C.R.); Department of Neurosurgery, Johns Hopkins University, Baltimore, Maryland (E.M.J.).
Brian HutzenCenter for Childhood Cancer and Blood Diseases, Research Institute at Nationwide Children's Hospital, Columbus, Ohio (A.W.S., B.H.); Nationwide Children's Hospital Department of Pathology and Laboratory Medicine and Departments of Pathology and Anatomy, The Ohio State University College of Medicine, Columbus, Ohio (C.R.P.); Animal Resources Core, Research Institute at Nationwide Children's Hospital, Columbus, Ohio (T.A.S.); Department of Neurological Surgery and Pediatrics, University of California, San Francisco, California (C.R.); Department of Neurosurgery, Johns Hopkins University, Baltimore, Maryland (E.M.J.).
Christopher R PiersonCenter for Childhood Cancer and Blood Diseases, Research Institute at Nationwide Children's Hospital, Columbus, Ohio (A.W.S., B.H.); Nationwide Children's Hospital Department of Pathology and Laboratory Medicine and Departments of Pathology and Anatomy, The Ohio State University College of Medicine, Columbus, Ohio (C.R.P.); Animal Resources Core, Research Institute at Nationwide Children's Hospital, Columbus, Ohio (T.A.S.); Department of Neurological Surgery and Pediatrics, University of California, San Francisco, California (C.R.); Department of Neurosurgery, Johns Hopkins University, Baltimore, Maryland (E.M.J.).
Terri A ShafferCenter for Childhood Cancer and Blood Diseases, Research Institute at Nationwide Children's Hospital, Columbus, Ohio (A.W.S., B.H.); Nationwide Children's Hospital Department of Pathology and Laboratory Medicine and Departments of Pathology and Anatomy, The Ohio State University College of Medicine, Columbus, Ohio (C.R.P.); Animal Resources Core, Research Institute at Nationwide Children's Hospital, Columbus, Ohio (T.A.S.); Department of Neurological Surgery and Pediatrics, University of California, San Francisco, California (C.R.); Department of Neurosurgery, Johns Hopkins University, Baltimore, Maryland (E.M.J.).
Corey RaffelCenter for Childhood Cancer and Blood Diseases, Research Institute at Nationwide Children's Hospital, Columbus, Ohio (A.W.S., B.H.); Nationwide Children's Hospital Department of Pathology and Laboratory Medicine and Departments of Pathology and Anatomy, The Ohio State University College of Medicine, Columbus, Ohio (C.R.P.); Animal Resources Core, Research Institute at Nationwide Children's Hospital, Columbus, Ohio (T.A.S.); Department of Neurological Surgery and Pediatrics, University of California, San Francisco, California (C.R.); Department of Neurosurgery, Johns Hopkins University, Baltimore, Maryland (E.M.J.).
Eric M JacksonCenter for Childhood Cancer and Blood Diseases, Research Institute at Nationwide Children's Hospital, Columbus, Ohio (A.W.S., B.H.); Nationwide Children's Hospital Department of Pathology and Laboratory Medicine and Departments of Pathology and Anatomy, The Ohio State University College of Medicine, Columbus, Ohio (C.R.P.); Animal Resources Core, Research Institute at Nationwide Children's Hospital, Columbus, Ohio (T.A.S.); Department of Neurological Surgery and Pediatrics, University of California, San Francisco, California (C.R.); Department of Neurosurgery, Johns Hopkins University, Baltimore, Maryland (E.M.J.).
Johns Hopkins University · USNationwide Children's Hospital · USUniversity of California, San Francisco · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAtypical teratoid rhabdoid tumor (AT/RT) is a rare, highly malignant pediatric tumor of the central nervous system that is usually refractory to available treatments. The aggressive growth, propensity to disseminate along the neuroaxis, and young age at diagnosis contribute to the poor prognosis. Previous studies have demonstrated the efficacy of using oncolytic measles virus (MV) against localized and disseminated models of medulloblastoma. The purpose of this study was to evaluate the oncolytic potential of MV in experimental models of AT/RT.

methodsFollowing confirmation of susceptibility to MV infection and killing of AT/RT cells in vitro, nude mice were injected with BT-12 and BT-16 AT/RT cells stereotactically into the caudate nucleus (primary tumor model) or lateral ventricle (disseminated tumor model). Recombinant MV was administered either intratumorally or intravenously. Survival was determined for treated and control animals. Necropsy was performed on animals showing signs of progressive disease.

resultsAll cell lines exhibited significant killing when infected with MV, all formed syncytia with infection, and all generated infectious virus after infection. Orthotopic xenografts displayed cells with rhabdoid-like cellular morphology, were negative for INI1 expression, and showed dissemination within the intracranial and spinal subarachnoid spaces. Intratumoral injection of live MV significantly prolonged the survival of animals with intracranial and metastatic tumors.

conclusionThese data demonstrate that AT/RT is susceptible to MV killing and suggest that the virus may have a role in treating this tumor in the clinical setting.

Indexed as

AnimalsBrainCell Line, TumorCell SurvivalChlorocebus aethiopsDisease Models, AnimalFemaleHumansKaplan-Meier EstimateMeasles virusMiceMice, NudeOncolytic VirotherapyOncolytic VirusesRhabdoid TumorVero Cellsatypical teratoid rhabdoid tumorintravenousmeasles virusoncolytic virus

Identifiers

PMID25838138
PMCPMC4633925
OpenAlexW2093117763

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.